Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
how do you manage atypical adenomatous hyperplasia (AAH) at the margin for 2 sites of the same lobe, in a patient with multiple GGO's s/p wedge resection?
Related Questions
Is there evidence supporting the role of SBRT in the management of oligometastatic stage IV NSCLC?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Is there a concern for using FFF beams in single isocenter multi target lung SBRT?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
Would you offer empiric lung SBRT for two growing FDG-avid lung lesions in a patient with severe COPD on oxygen?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
